Expression of highly active recombinant NS3 protease domain of hepatitis C virus in E. coli  by Vishnuvardhan, Daesety et al.
FEBS 18138 FEBS Letters 402 (1997) 209-212 
Expression of highly active recombinant NS3 protease domain of 
hepatitis C virus in E. coli 
Daesety Vishnuvardhana, Nobuko Kakiuchib, Petri T. Urvila, Kunitada Shimotohnob, 
P.K.R. Kumara'*, Satoshi Nishikawaa 
^National Institute of Bioscience and Human Technology, AIST, 1-1 Higashi, Tsukuba, Ibaraki 305, Japan 
b Virology Division, National Cancer Center Research Institute, Tsukiji, Tokyo 104, Japan 
Received 22 November 1996 
Abstract The serine protease domain of HCV comprising 
amino acids 1027-1218 (ANS3) was expressed in E. coli with a 
His tag at its N-terminal end. The protease was purified to 
apparent homogeneity by a single step affinity chromatography 
resulting in high yields ( ~ 3 mg/1 of cultured cells). The ANS3 
efficiently cleaves a 17-mer peptide corresponding to the NS5A-
NS5B junction with kcJKm - 160 X10~* min
 f \MTX in the 
presence of NS4A peptide. Our ANS3 represents the minimal 
domain possessing highly active protease of NS3 constructed so 
far. The ANS3 protein also efficiently processed a longer 
substrate corresponding to NS5A/5B junction (2203-2506 amino 
acids) that was synthesized by in vitro transcription and 
translation system. 
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1. Introduction 
Hepatitis C virus (HCV) is the major etiological agent of 
post-transfusion non-A, non-B hepatitis, is an enveloped virus 
containing a single-stranded RNA genome of approximately 
9.5 kb nucleotides [1,2]. A single polyprotein of 3010-3030 
amino acids is translated from this genome [3] in the order 
of NH2-C-El-E2-p7-NS2-NS3-NS4A-NS4B-NS5A-NS5B-
COOH (Fig. 1A) [4,5]. This polyprotein is subsequently proc-
essed by a combination of host and viral proteases to produce 
at least 10 viral proteins. The core protein (C) and envelope 
proteins (El and E2) are structural proteins, and NSs are non-
structural proteins [6,7]. 
Previous studies indicate that a host signal peptidase local-
ized in endoplasmic reticulum (ER) catalyzes polyprotein 
cleavages in the structural region (C/El, E1/E2, E2/p7 and 
p7/NS2) [8,5], whereas a HCV encoded serine protease located 
in the N-terminal one-third of the NS3 protein is responsible 
for cleavages at four sites (3/4A, 4A/4B, 4B/5A and 5A/5B) 
(Fig. 1A) [9-14] in the NS region. Using a transient coexpres-
sion system it has been shown that proteolytic cleavages in the 
non-structural protein region (NS3 to NS5B) of HCV poly-
protein are effected by two viral proteins, NS3 and NS4A [15-
19]. The N-terminal 180 amino acid region of NS3 includes 
sequences showing homology with the active sites of serine 
proteases [20-22]. Histidine 1083, aspartate 1107 and serine 
1165 (numbers are according to their locations in the poly-
protein of HCV subtype J (HCV-Ib) [23,24]) found in this 
domain have been proposed to constitute the catalytic triad 
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of the NS3 protease similar to other serine proteases belong-
ing to the chymotrypsin family. 
NS4A is shown to be the NS3 protease cofactor or effector 
enhancing cleavage efficiency at various sites NS3/4A, NS4A/ 
4B, NS4B/5A and NS5A/5B [16,19,25-27]. NS4A is an am-
phipathic protein of 54 amino acids and it has a very hydro-
phobic N-terminal domain followed by a hydrophilic C-ter-
minal domain [16]. Using an in vitro reconstituted assay 
system it has been shown that the residues 22-31 of NS4A 
constitute the putative core sequence for NS4A's effector ac-
tivity [27]. The mechanism by which NS4A facilitates cleavage 
remains obscure. Truncation experiments have mapped the 
N-terminus of NS3 as the domain responsible for interaction 
with NS4A [25,27]. 
Since the NS3 protein is very important for releasing func-
tional proteins from the polyprotein, it is currently being tar-
geted in the development of drugs and diagnostics. As a mat-
ter of fact, several known serine protease inhibitors have been 
tested for their action on NS3 activity in vitro and it was 
found that millimolar concentrations of these compounds 
were required to show moderate inhibitory effect on NS3 pro-
tease activity [3,28]. One major obstacle for these well known 
inhibitors may be the presence of helicase domain also or 
alternatively NS3 protease may be structurally different in 
comparison with other serine protease domains. 
In order to carry out detailed characterization of this en-
zyme in terms of its substrate specificity, kinetics, sensitivity to 
inhibitors and for structural studies, a reproducible and con-
venient large-scale purification of the enzymatically active 
protease domain of NS3 is essential. In this report we show 
that the region encompassing amino acids 1027-1218 tagged 
with the His tail (6 His) has greater activity than other ex-
pression constructs made so far and the purification procedure 
is much simpler. We also show that the purified protein pos-
sesses the ability to interact with NS4A resulting in increased 
proteolytic activity. 
2. Materials and methods 
2.1. Construction of expression plasmid containing the HCV 
serine protease domain 
To construct the expression plasmid pHisBANS3, a cDNA frag-
ment encoding amino acid residues 1027-1218 in the HCV polypro-
tein was obtained by PCR using appropriate oligonucleotides (1: 
d(CCGCTGCAGCCATGGCGCCTATCACGGCCTAT), 2: d(CC-
GAAGCTTTCAGGCCGGAGGGGATGAGTT)), which insert a 
PstI site at the 5'-end and a TAG (stop) codon and Hindlll site at 
the 3'-end of the sequence. We used plasmid pMANS34NSH [29] as a 
template to amplify amino acid residues 1027-1218 in the HCV poly-
protein. The PCR product amplified using Ex. Taq (Takara) was first 
cloned into pCR II vector (Invitrogen) according to the manufactur-
0014-5793/97/S17.00 © 1997 Federation of European Biochemical Societies. All rights reserved. 
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Fig. 1. Schematic representation of HCV serine proteinase domain 
expressed in E. coli. A: The HCV genome and a translated product 
with names of the processed proteins. The filled arrow shows the 
cleavage site of HCV serine protease, whereas the dotted arrow in-
dicates the cleavage site of HCV metaloprotease. B: ANS3. Closed 
and open boxes indicate the 6 histidine tag and the protease do-
main, respectively. C: N-terminal extra amino acid sequence and 
NS3 protease domain. 
er's instructions and digested with Pstl and Hindlll to release the 
fragment encompassing amino acids 1027-1218 of HCV poly protein. 
It was subsequently cloned into expression plasmid pTrcHisB (Invi-
trogen) which was also digested with Pstl and Hindlll. The resulting 
plasmid pHisBANS3 (Fig. 1B,C) encodes the protease domain of NS3 
(192 amino acids) with a N-terminal 40 non-virus encoded amino 
acids possessing a consecutive stretch of 6 His residues that allows 
fusion protein to be purified in a single step by metal chelating affinity 
chromatography. The cloned DNA fragment was sequenced in order 
to exclude the introduction of mutations by PCR and also to confirm 
the in-frameness of the insert. 
2.2. Expression and purification of HCV NS3 protease domain 
Following transformation of E. coli HB101, cells harboring the 
vector pHisBANS3 were grown in LB medium containing 100 |xg/ml 
ampicillin. When the absorbance reached a value of 0.5-0.6 OD60o 
isopropyl-1-thio-ß-D-galactopyranoside (IPTG) was added to give a 
final concentration of 1 mM and the incubation was continued for 
an additional 2 h at 37°C. Under this induction condition a high level 
expression of ANS3 was observed and there was only a small amount 
present in the insoluble fraction. The cells were harvested by centrif-
ugation and washed extensively with PBS (20 mM sodium phosphate; 
pH 7.4, 140 mM NaCl). The cell pellet was resuspended in lysis buffer 
(20 mM sodium phosphate; pH 6.3, 500 mM NaCl) and disrupted by 
sonication on ice using a Branson 200 sonifier (30 sX6 strokes at 18 
W output with 30 s intervals). The homogenate was centrifuged at 
30000Xg for 30 min to remove cell debris and was chromatographed 
on a nickel-agarose column (Qiagen). We applied a stepwise gradient 
of pH to elute the protease in order to overcome the precipitation of 
the enzyme. The column was washed extensively with several column 
volumes of lysis buffer and subsequently washed using the same buffer 
of pH 6.0 and finally with the same buffer of pH 5.0. Resin bound 
protein was eluted with sodium phosphate buffer (pH 4.0) containing 
500 mM NaCl. Eluted fractions were subjected to SDS-PAGE [30], 
protein containing fractions were pooled and concentrated by using 
Millipore Ultrafree Biomax 10K concentrator (Millipore). The en-
zyme was stored in aliquots at —20°C in the same buffer containing 
40% glycerol. 
Protein concentrations were estimated from UV absorbance at 
280 nm: an extinction coefficient of e = 20 800 M _ 1 cm - 1 was calcu-
lated on the basis of primary sequence data according to published 
procedures [31] and concentration of ANS3 was determined according 
to the Lambert Beer law. Alternatively, ANS3 concentration was de-
termined by Bradford (BioRad) assay using lysozyme as standard. 
2.3. HCV NS3 protease assays 
To characterize the enzymatic activity of the purified protease 
(ANS3) we investigated its ability to cleave a synthetic peptide, S-l 
(Dns-Gly-Glu-Ala-Gly-Asp-Asp-Ile-Val-Pro-Cys-A-Ser-Met-Ser-Tyr-
Thr-Trp-Thr-COOH, A; cleavage site) corresponding to the cleavage 
site of the NS5A/5B. Protease activity of ANS3 and maltose binding 
NS3 fusion protein, MBP-NS3 (amino acids 985-1647) [29] was ana-
lyzed either in the presence or absence of NS4A peptide, P41 (amino 
acids 1673-1692 of HCV polyprotein). 
Kinetic constants were determined from enzyme assays with the 
synthetic substrate concentration ranging from 25 to 960 (J.M. The 
Km and kclit values were determined by Lineweaver-Burk plots. Ki-
netic reactions were analyzed either in the presence or absence of P41. 
For evaluating the rate of reaction in the absence of P41, the ANS3 or 
MBP-NS3 (0.72 mM) was incubated with various concentrations of 
substrate in a buffer (Tris-HCl (pH 7.8), 30 mM NaCl2, 5 mM CaCl2, 
10 mM DTT) at 25°C for 60 min, whereas reactions carried out in the 
presence of P41 (10 mM) were initially equilibrated with ANS3 or 
MBP-NS3 for 15 min at 37°C in the above buffer. The reaction was 
initiated by addition of substrate at 37°C and data points were col-
lected for 10 min. 
In order to test the ability of the ANS3 to cleave longer substrate 
representing NS5A/B junction protein in the amino acid sequence 
2203-2506 of HCV polyprotein which closely resembles the situation 
in vivo, radiolabelled NS5A/5B substrate was produced using a 
coupled transcription-translation system (TNT Promega) according 
to the manufacturer's protocol. The DNA encoding amino acids 
2203-2506 of polyprotein representing the NS5A/B site was amplified 
by PCR and was added to a 25 ul TNT reaction in the presence of 
[35S]methionine (Amersham) at 300 |xCi/ml and incubated at 30°C for 
1-2 h. For experiments to assess proteolytic cleavage of pre-formed 
substrate the TNT reaction mixture was diluted by adding an equal 
volume of buffer (100 mM HEPES (pH 7.6), 300 mM NaCl, 6 mM 
MgCl2, 20 mM DTT). To 6 ul ( = 300 cpm of translated product) of 
diluted TNT reaction mixture, ANS3 (750 nM) was added and incu-
bated for 30 min at 30°C. In experiments to study the effect of NS4A 
peptide, the protease was pre-incubated with P41 for 5 min at 30°C 
before the addition of substrate. Samples were withdrawn at different 
time intervals and the reaction was stopped by adding SDS-PAGE 
sample buffer followed by denaturing at 95°C for 3 min. All samples 
were loaded on to SDS-PAGE and the radioactivity was quantitated 
by image analyzer (BAS 2000, Fuji Film). 
3. Results and discussion 
The purified ANS3 protease migrated as a single band with 
a molecular mass consistent with that calculated from the 
primary sequence (molecular mass of 25 k D a as judged 
from SDS-PAGE) (Fig. 2). The final yield was ~ 3 mg of 
purified protein per liter of cultured cells and the purity of 
the prepárate was estimated to be over 95% as judged by SDS 
gel. Though several constructs have been reported for the 
expression of the NS3, considering the yield and the simplicity 
of the purification procedure which we described here offers 
clear advantage for structural studies, wherein large amounts 
of enzyme are required. Table 1 shows that in the absence of 
P41 the Km of ANS3 was 250 u M and £c a t was 2.0 min"
1 . In 
Table 1 

























"Data are the mean values from three independent experiments. 
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Fig. 2. Purification of the NS3 protease domain. Samples deriving 
from single steps of the purification were loaded on an SDS-15% 
polyacrylamide gel, and bands were visualized by Coomassie stain-
ing. Lane 1: molecular mass markers; lane 2: homogenate from E. 
coli without construct; lane 3; homogenate from pTrcHisBANS3; 
lane 4: 750 ng of purified ANS3 after affinity chromatography; lane 
5: 1.5 (ig of purified ANS3 after affinity chromatography. 
contrast, in the presence of a 10-fold molar excess of P41 the 
Km (99 uM) was about 2.5 times lower than that in the case of 
ANS3 alone, and the kc&i (15.8 min
- 1) was about 8 times 
higher than that for ANS3 alone. As a result the kcJKm value 
increased 20 times in the presence of P41. When we compared 
the kcJKm value of MBP-NS3, ANS3 protease activity was 
increased to 2-fold in the absence and 6-fold in the presence of 
P41. Our ANS3 protease activity was found to be the highest 
reported so far. The data presented above suggest that region 
1027-1218 represents the minimal domain required for the 
protease activity, since the region 1027-1218 exemplifies all 
the cleavage kinetics of the MBP-NS3 (985-1647) reported 
earlier [27]. 
The coefficient for proteolytic efficiency was comparable to 
that of two reports published recently [27,32], whereas the Km 
and fccat values are comparable with only that of NS3 (encom-
passing both the protease and helicase domains fused to 
MBP) [27]. In the case of ANS3, the presence of P41 clearly 
increases the affinity for the substrate (as evident from Km 
values) and thereby increases the catalytic rate (Table 1). Shi-
mizu et al. [27] have made a similar observation with NS3 
which has both protease and helicase functional domains, 
whereas Steinkuhler et al. [32] have expressed NS3 protease 
domain encompassing amino acids 1038-1226 of HCV poly-
protein and analyzed its activity on NS4A/NS4B cleavage site 
both in the presence and in the absence of NS4A protein. 
Though the kinetic differences were observed using a peptide 
derived from a NS4A-independent cleavage site (NS4A/4B), 
the data clearly show the activation role of NS4A in altering 
the NS3 activity in general. However, the affinity (Km) was 
not altered in the presence of NS4A as evident from their 
Fig. 3. TNT analysis of cleavage of NS5A/5B substrate by ANS3. 
Substrate representing NS5A/5B incubated, lane 1: without ANS3; 
lane 2: with ANS3; lane 3: with both ANS3 and P41. All samples 
were incubated at 30°C for 30 min; proteins were labelled with 
[35S]methionine and analyzed by SDS-PAGE followed by fluorogra-
phy. 
published data. This may possibly be due to the absence of 
essential N-terminal amino acids for interaction with NS4A in 
their expressed protease domain. The fact that NS4A can 
interact with ANS3 in a similar way as with full NS3 and 
brings about similar changes confirms that ANS3 despite its 
truncated version and fusion retains the favorable conforma-
tion for interaction. Based on the above observations we can 
conclude that amino acid residues 1027-1218 are sufficient to 
represent the complete protease function of NS3 even consid-




Fig. 4. TNT analysis on effect of P41 on ANS3 rate of cleavage. 
Normalized cleavage % is shown against different time intervals. 
Without P41 (D) and with P41 (O). 
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the regulation and the substrate requirements of the protease 
are expected to offer further insights into the mechanism of 
activation by P41. 
In addition, when we tested the ability of ANS3 to cleave a 
longer substrate representing the NS5A/B junction, as shown 
in Fig. 3, ANS3 could cleave the NS5A/B junction protein 
(amino acids 2203-2506) in close agreement with the observa-
tion when the small synthetic peptide substrate NS5A/B was 
used. The addition of P41 again clearly enhanced the cleavage 
reaction. F rom the time course of these reactions (Fig. 4) the 
rate of cleavage was stimulated more than 2-fold by the addi-
tion of P41. Since the purified recombinant ANS3 protease has 
a relatively smaller molecular size, representing the complete 
catalytic function of NS3 protease, and considering the ease 
and yield of purification, we believe that it is an ideal candi-
date to generate further studies elucidating the structure-func-
tion relationships, mechanism of interaction with NS4A pep-
tide as well as developing protease inhibitors. 
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